💊 Get Accurate, Objective, and Timely Intelligence From DrugPatentWatch
Profile for MediciNova, Inc. (MNOV)
« Back to company indexMNOV Chatter Timeline
Stock Ticker for MNOV
Most Active Tweeters for MNOV
| User | Tweets |
|---|---|
| @ElRbkWynVNX7U43 | 2 |
| @investipp1 | 2 |
| @Tickeron | 2 |
| @JawaharDatta4 | 1 |
| @ahighelevation | 1 |
Recent Tweets for MNOV
 |
@spencer32922602 Entries & exits Daily! Discord link below? https://t.co/sFE29IK4Pu $MNOV May 27th 2022, 8:05pm |
 |
@ElRbkWynVNX7U43 RT @ahighelevation: $MNOV Data for ARDS Trial in COVID-19 Patients Expected Soon #drugdevelopment #smallcaps - https://t.co/Zv9UKPTGss http… May 26th 2022, 8:05pm |
 |
@ahighelevation $MNOV Data for ARDS Trial in COVID-19 Patients Expected Soon #drugdevelopment #smallcaps - https://t.co/Zv9UKPTGss https://t.co/X90CsuMmMc May 26th 2022, 4:05pm |
|
@ElRbkWynVNX7U43 RT @ZacksSmallCap: $MNOV: @MediciNova_US - Plans For Phase 2 Study Of MN-001 (Tipelukast) In NAFLD Patients With Type 2 Diabetes And Hypert… May 25th 2022, 8:05pm |
 |
@PratikS77932094 Key level to watch $MNOV https://t.co/UkrsnaMyIJ May 25th 2022, 4:05pm |
 |
@ZacksSmallCap $MNOV: @MediciNova_US - Plans For Phase 2 Study Of MN-001 (Tipelukast) In NAFLD Patients With Type 2 Diabetes And H… https://t.co/qpxjkSFSSw May 25th 2022, 2:05pm |
 |
@SparkNewswire $MNOV MediciNova Shares Quiet But See Large Volume Spike Following Circulation Of Zack’s Small Cap Research N… https://t.co/yFseOi711p May 25th 2022, 2:05pm |
 |
@bthefirsttoknow First out// $MNOV: MediciNova Shares Quiet But See Large Volume Spike Following Circulation Of Zack's Small Cap… https://t.co/1tRepxrYwY May 25th 2022, 2:05pm |
 |
@Tickeron $MNOV's price moved below its 50-day Moving Average on May 5, 2022. View odds for this and other indicators:… https://t.co/vLHEG3DkTZ May 23rd 2022, 5:05am |
 |
@investipp1 Top3 highest deviation until the analysts median target prices as of 2022/05/19: 1. $MNOV - #MediciNova, Inc. (+458… https://t.co/6sNocro1aK May 20th 2022, 3:05am |
|
@investipp1 Top3 highest deviation until the analysts median target prices as of 2022/05/17: 1. $MNOV - #MediciNova, Inc. (+452… https://t.co/qrVyO4tjgX May 18th 2022, 3:05am |
 |
@JawaharDatta4 $MNOV ~Hey guys don't miss the next Move in a few hours. https://t.co/YHUlEFNqXe May 17th 2022, 5:05pm |
|
@Tickeron $MNOV's price moved below its 50-day Moving Average on May 5, 2022. View odds for this and other indicators:… https://t.co/e7F7T0tpX8 May 15th 2022, 6:05pm |
|
@Tickeron Is this good for your portfolio? $MNOV RSI Indicator left the oversold zone. #Medicinova #stockmarket #stock… https://t.co/km8FpyqimA May 14th 2022, 11:05pm |
 |
@newsfilterio Form S-8 (securities to be offered to employees in employee benefit plans) filed with the SEC $MNOV https://t.co/eU3dowPN8M May 14th 2022, 2:05am |
 |
@SurajCh57717434 $MNOV ~Hey guys don't miss the next Move in a few hours. https://t.co/2lGqKYCUY5 May 11th 2022, 6:05pm |
|
@SurajCh57717434 $MNOV ~Hey guys don't miss the next Move in a few hours. https://t.co/2lGqKYCUY5 May 11th 2022, 3:05pm |
 |
@alerts_real $MNOV All that you need to know,,, Shorts haven't covered a single share,, Come join us for free https://t.co/6YesXV6dRW May 10th 2022, 2:05pm |
 |
@BhattTrishana $MNOV ~Hey guys don't miss the next Move in a few hours. https://t.co/N9nosiBgN7 May 7th 2022, 1:05pm |
 |
@RamDial4 $MNOV ~Hey guys don't miss the next Move in a few hours. https://t.co/j6PkQ3PQ9T May 4th 2022, 3:05pm |
|
@RamDial4 $MNOV ~Hey guys don't miss the next Move in a few hours. https://t.co/j6PkQ3PQ9T May 4th 2022, 12:05pm |
|
@Tickeron $MNOV in -10.92% Downtrend, declining for three consecutive days on April 27, 2022. View odds for this and other in… https://t.co/iGT58QqFsn May 1st 2022, 12:05pm |
|
@Tickeron Medicinova to report earnings on May 02, 2022. Earnings per share (EPS) estimate: $-0.13 $MNOV #Medicinova… https://t.co/CO8DhU73tm May 1st 2022, 6:05am |
|
@Tickeron $MNOV enters a Downtrend because Momentum Indicator dropped below the 0 level on April 25, 2022. View odds for this… https://t.co/XGX2L6pcSf April 29th 2022, 5:04am |
 |
@FlashAlert_me $MNOV [15s. delayed] filed form DEF 14A on April 26, 16:15:32 https://t.co/iaJq6PvgzC April 26th 2022, 8:04pm |
 |
@hesham_monica $MNOV (NASDAQ) Stock Rating Upgraded to Buy: Medicinova Inc >> https://t.co/hskqdI0YOV April 25th 2022, 1:04pm |
|
@Tickeron How does this affect your portfolio? $MNOV MACD Histogram turned negative on April 22, 2022. #Medicinova… https://t.co/SsE9Y6qbzk April 23rd 2022, 11:04am |
 |
@StckPro $MNOV NEW ARTICLE : MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference… https://t.co/FWrNCyT1tn April 21st 2022, 11:04pm |
|
@FlashAlert_me $MNOV [15s. delayed]: Issued Press Release on April 21, 19:00:00: MediciNova to Participate in the B. Riley Neuro &… https://t.co/h12q7k63pK April 21st 2022, 11:04pm |
 |
@AnkitaDalal15 $MNOV Earnings reports today before the markets open. https://t.co/0xMye6SFB4 April 21st 2022, 10:04am |
|
@Tickeron $MNOV's in Uptrend: Moving Average Convergence Divergence (MACD) Histogram crosses above signal line. View odds for… https://t.co/iFZTXtNWuc April 21st 2022, 9:04am |
 |
@thudderwicks $MNOV "MIF inhibition with MN-166 (ibudilast) may prevent metastatic spread in uveal melanoma patients and help to… https://t.co/VoJJSdIJKg April 21st 2022, 7:04am |
|
@thudderwicks $MNOV "This study provided the first in vivo evidence that MIF inhibition may serve as a novel adjuvant drug therap… https://t.co/UiKWL0gKpe April 21st 2022, 7:04am |
|
@thudderwicks $MNOV announces publication of MN-166 data https://t.co/G1haAZTvkX April 21st 2022, 7:04am |
|
@Tickeron $MNOV's in Uptrend: Moving Average Convergence Divergence (MACD) Histogram just turned positive. View odds for this… https://t.co/KbqqLNlLqR April 21st 2022, 1:04am |
|
@StckPro $MNOV NEW ARTICLE : MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis… https://t.co/p1zdWIbcdY April 20th 2022, 11:04pm |
|
@bthefirsttoknow First out// $MNOV: MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis i… https://t.co/yvFtCfmFe2 April 20th 2022, 11:04pm |
|
@Tickeron $MNOV's price moved above its 50-day Moving Average on March 17, 2022. View odds for this and other indicators:… https://t.co/fpsjauuIep April 19th 2022, 9:04pm |
 |
@LeeSinTrade1 $MNOV Trade Ideas | Awaiting Short Signal. Free trial at https://t.co/z9Zossz5Nf https://t.co/ngWKdHrlKx April 19th 2022, 3:04pm |
 |
@MaiteMerenda $MNOV Awaiting Short Signal. ? Day Trading by UltraAlgo https://t.co/ArLutxD8xt April 19th 2022, 11:04am |
|
@hesham_monica $MNOV (NASDAQ) Stock Rating Upgraded to Buy: Medicinova Inc >> https://t.co/HP92ksRWGC April 19th 2022, 12:04am |
 |
@SunitaP11530258 $MNOV Earnings reports today before the markets open. https://t.co/BAbTfVmzdj April 18th 2022, 4:04pm |
 |
@TradingChromat1 $MNOV Awaiting Short Signal. Learn more at https://t.co/emZsi1kAMx https://t.co/l7qa4RJOU5 April 18th 2022, 4:04pm |
|
@Tickeron $MNOV's 10-day Moving Average moved above its 50-day Moving Average on March 23, 2022. View odds for this and other… https://t.co/O8HvnNNOu1 April 13th 2022, 8:04pm |
 |
@MrDollawilly $MNOV Want to see it close over $3 April 13th 2022, 7:04pm |
|
@MrDollawilly $MNOV Just check the daily chart April 13th 2022, 2:04pm |
 |
@MarcJacksonLA $MNOV MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospital… https://t.co/QG4Ro48vYr April 13th 2022, 12:04pm |
 |
@vitalhongkong RT @stock_titan: $MNOV MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized CO… April 13th 2022, 6:04am |
|
@Tickeron $MNOV's 10-day Moving Average broke above its 50-day Moving Average on March 23, 2022. View odds for this and other… https://t.co/v1aOaqAOrb April 13th 2022, 6:04am |
|
@FlashAlert_me $MNOV [15s. delayed]: Issued Press Release on April 12, 23:00:00: MediciNova Announces Completion of Enrollment in… https://t.co/9fLYgZfGOL April 13th 2022, 3:04am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2022. All rights reserved.